# Initial Treatment With Bevacizumab in Choroidal Neovascularization Associated to High Myopia

> **NCT01716026** · PHASE3 · COMPLETED · sponsor: **Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA** · enrollment: 66 (actual)

## Conditions studied

- Choroidal Subfoveal/Juxtafoveal Neovascularization in High Myopia

## Interventions

- **DRUG:** Bevazizumab intravitreal injection

## Key facts

- **NCT ID:** NCT01716026
- **Lead sponsor:** Instituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-10
- **Primary completion:** 2018-04
- **Final completion:** 2018-04
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2023-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01716026

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01716026, "Initial Treatment With Bevacizumab in Choroidal Neovascularization Associated to High Myopia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01716026. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*